Anthony L. DeVico
YOU?
Author Swipe
View article: Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation
Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation Open
Broadly neutralizing antibodies (bnAbs) against HIV hold promise as therapeutic and prophylactic agents, but realizing this potential requires antibodies that function across the antigenic heterogeneity of the HIV envelope glycoprotein (En…
View article: ACE2 Receptor and Antibody Binding to SARS-CoV-2 Spikes and Virions by Single-Molecule Fluorescence
ACE2 Receptor and Antibody Binding to SARS-CoV-2 Spikes and Virions by Single-Molecule Fluorescence Open
The envelope (Env) spike (S) trimers of known SARS-CoV-2 strains have evolved to display conformational fluctuations between structural states, which in turn impact host receptor binding efficiency, the mechanism of infection, and suscepti…
View article: Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo
Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo Open
This study addresses a challenge in the administration of monoclonal antibodies (mAbs). Intravenous administration requires additional resources, including nursing staff, making it time-consuming and costly. Although subcutaneous (SC) admi…
View article: A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV Open
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with …
View article: Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive Analysis
Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive Analysis Open
N49P9.6-FR-LS and PGT121 are promising antibodies with significant therapeutic potential against HIV infection, but they are prone to precipitation at high concentrations. This study evaluates the influence of six excipients—L-arginine, L-…
View article: Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins
Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins Open
Efforts to develop vaccine and immunotherapeutic countermeasures against the COVID-19 pandemic focus on targeting the trimeric spike (S) proteins of SARS-CoV-2. Vaccines and therapeutic design strategies must impart the characteristics of …
View article: HIV-Associated Lymphoma in an Urban Clinic Population: Epidemiology and Outcomes during the Antiretroviral Therapy Era
HIV-Associated Lymphoma in an Urban Clinic Population: Epidemiology and Outcomes during the Antiretroviral Therapy Era Open
Introduction- People living with human immunodeficiency virus (HIV) infection (PLWH) are at increased risk for Hodgkin and non-Hodgkin lymphoma. Incidence of HIV-associated lymphoma fell dramatically after the introduction of combined anti…
View article: Evidence of variable human Fcγ receptor-Fc affinities across differentially-complexed IgG
Evidence of variable human Fcγ receptor-Fc affinities across differentially-complexed IgG Open
Antibody-mediated effector functions are widely considered to unfold according to an associative model of IgG-Fcγ receptor (FcγR) interactions. The associative model presupposes that Fc receptors cannot discriminate antigen-bound IgG from …
View article: Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer
Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer Open
Non-small cell lung cancer (NSCLC) is the most fatal non-AIDS defining cancer in people living with HIV (PWH) on antiretroviral therapy (ART). Treatment of malignancies in PWH requires concomitant cancer therapy and ART, which can lead to …
View article: Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s
Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s Open
Passive transfer of monoclonal antibodies (mAbs) of human origin into Non-Human Primates (NHPs), especially those which function predominantly by a Fc-effector mechanism, requires an a priori preparation step, in which the human mAb is ree…
View article: Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial Open
A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was…
View article: Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement
Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement Open
Monoclonal antibodies represent one of the most important recent innovations in the fight against infectious diseases. Although potent antibodies can be cloned from infected individuals, various strategies can be employed to improve their …
View article: Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays
Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays Open
There is an urgent need for an accurate antibody test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have developed 3 ELISA methods, trimer spike IgA, trimer spike IgG, and nucleocapsid IgG, for detecting anti-SARS-Co…
View article: Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays
Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays Open
There is an urgent need for an accurate antibody test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this paper, we have developed 3 ELISA methods, trimer spike IgA, trimer spike IgG, and nucleocapsid IgG, for detecti…
View article: Retraction for Khattar et al., “Newcastle Disease Virus Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces Strong Mucosal and Serum Antibody Responses in Guinea Pigs”
Retraction for Khattar et al., “Newcastle Disease Virus Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Induces Strong Mucosal and Serum Antibody Responses in Guinea Pigs” Open
It has been called to our attention that some lanes of Fig. 3, 5, and 10 have used the wrong samples.These mistakes happened during the assembly of the figures.We are taking responsibility for the mistakes and retracting the paper.S.K.
View article: 2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial
2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial Open
Background A primary challenge for HIV vaccine development is to raise antiviral antibodies capable of recognizing highly variable viral antigens. The full-length single chain (FLSC) gp120-CD4 chimeric protein was designed to present a hig…
View article: Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure
Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure Open
The trimeric envelope spikes on the HIV-1 virus surface initiate infection and comprise key targets for antiviral humoral responses. Circulating virions variably present intact envelope spikes, which react with neutralizing antibodies; and…
View article: Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response
Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response Open
It is widely believed that protection against acquisition of HIV or SIV infection requires anti-envelope (anti-Env) antibodies, and that cellular immunity may affect viral loads but not acquisition, except in special cases. Here we provide…
View article: Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell‐mediated cytotoxicity assay
Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell‐mediated cytotoxicity assay Open
Several different assay methodologies have been described for the evaluation of HIV or SIV‐specific antibody‐dependent cell‐mediated cytotoxicity (ADCC). Commonly used assays measure ADCC by evaluating effector cell functions, or by detect…
View article: Patterns of conserved gp120 epitope presentation on attached HIV-1 virions
Patterns of conserved gp120 epitope presentation on attached HIV-1 virions Open
Significance A complete picture of HIV antigenicity during early replication is needed to elucidate the full range of options for controlling infection through humoral immunity. The HIV envelope protein, gp120, experiences key structural r…
View article: Survivors Remorse: antibody‐mediated protection against <scp>HIV</scp>‐1
Survivors Remorse: antibody‐mediated protection against <span>HIV</span>‐1 Open
Summary It is clear that antibodies can play a pivotal role in preventing the transmission of HIV ‐1 and large efforts to identify an effective antibody‐based vaccine to quell the epidemic. Shortly after HIV ‐1 was discovered as the cause …
View article: Human T <sub>h</sub> 17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection
Human T <sub>h</sub> 17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection Open
Human immunodeficiency virus (HIV) infects and depletes CD4 + T cells, but subsets of CD4 + T cells vary in their susceptibility and permissiveness to infection. For example, HIV preferentially depletes interleukin-17 (IL-17)-producing T h…